Fedratinib (Inrebic) for ruxolitinib-resistant / intolerant PMF
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-FEDRATINIB |
|---|
| ID | REG-FEDRATINIB-PMF |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-JAKARTA2-HARRISON-2017 SRC-NCCN-MPN-2025 |
Notes
Selective JAK2 inhibitor for MF post-ruxolitinib failure or intolerance. JAKARTA-2 phase-2 + FREEDOM-2 phase-3 confirmatory. Wernicke encephalopathy boxed warning — mandatory thiamine measurement + supplementation. Take with food. STUB — pending Co-Lead sign-off.
Used By
Indication
IND-PMF-2L-FEDRATINIB- IND-PMF-2L-FEDRATINIB